Skip to content
10-Q

Quarterly Report

Monopar Therapeutics MNPR

0001437749-26-016982

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 6.7M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.47M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.66M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $52.54M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $61.83M
Stockholders Equity Q1 2026 · Mar 31, 2026 $135.39M
Stockholders Equity Q1 2026 · Dec 31, 2025 $137.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 $53.59M
Stockholders Equity Q1 2026 · Dec 31, 2024 $55.04M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.46M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.74M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.59M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.89M
Current Assets Q1 2026 · Mar 31, 2026 $137.74M
Current Assets Q1 2026 · Dec 31, 2025 $140.46M
Total Assets Q1 2026 · Mar 31, 2026 $137.98M
Total Assets Q1 2026 · Dec 31, 2025 $140.72M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.46
Eps Basic Q1 2026 · Mar 31, 2025 −$0.38
Sga Expense Q1 2026 · Mar 31, 2026 $1.74M
Sga Expense Q1 2026 · Mar 31, 2025 $1.58M
Rd Expense Q1 2026 · Mar 31, 2026 $3.49M
Rd Expense Q1 2026 · Mar 31, 2025 $1.64M
Net Income Q1 2026 · Mar 31, 2026 −$3.89M
Net Income Q1 2026 · Mar 31, 2025 −$2.62M
Operating Income Q1 2026 · Mar 31, 2026 −$5.23M
Operating Income Q1 2026 · Mar 31, 2025 −$3.22M
Revenue Q1 2026 · Mar 31, 2026 $0